Outcomes of coronavirus disease 2019 in patients with neuromyelitis optica and associated disorders.
Eur J Neurol
; 28(10): 3461-3466, 2021 Oct.
Article
em En
| MEDLINE
| ID: mdl-33103295
ABSTRACT
BACKGROUND:
Outcomes of coronavirus disease 2019 (COVID-19) in patients with neuromyelitis optica spectrum disorders (NMOSD) or myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD), often treated with immunosuppressive therapies, are still unknown.METHODS:
We conducted a multicenter, retrospective, observational cohort study among all French expert centers for neuromyelitis optica and related disorders. Patients with NMOSD or MOGAD included in the study received a confirmed or highly suspected diagnosis of COVID-19 between 1 March 2020 and 30 June 2020. Main outcome was COVID-19 severity score assessed on a seven-point ordinal scale ranging from 1 (not hospitalized with no limitations on activities) to 7 (death).RESULTS:
Fifteen cases (mean [SD] age 39.3 [14.3] years, 11 female) were included. Five patients (33.3%) were hospitalized, all receiving rituximab. A 24-year-old patient with positive aquaporine-4 antibody, with obesity as comorbidity, needed mechanical ventilation. Outpatients were receiving anti-CD20 (5), mycophenolate mofetil (3) or azathioprine (3). They were younger (mean [SD] age 37.0 [13.4] years), with a longer disease duration (mean [SD] 8.3 [6.3] years) and had a lower expanded disability severity score (EDSS) score (median [range] EDSS 2.5 [0-4]) relative to patients requiring hospitalization (mean [SD] age 44.0 [16.4] years, mean [SD] disease duration 5.8 [5.5] years, median [range] EDSS 4 [0-6.5]).CONCLUSIONS:
COVID-19 outcome was overall favorable in this cohort. Larger international studies are needed to identify risk factors of severe COVID-19; however, we recommend personal protective measures to reduce risk of SARS-CoV-2 infection in this immunocompromised population.Palavras-chave
Texto completo:
1
Base de dados:
MEDLINE
Assunto principal:
Neuromielite Óptica
/
COVID-19
Tipo de estudo:
Observational_studies
/
Prognostic_studies
/
Risk_factors_studies
Limite:
Adult
/
Female
/
Humans
Idioma:
En
Revista:
Eur J Neurol
Assunto da revista:
NEUROLOGIA
Ano de publicação:
2021
Tipo de documento:
Article
País de afiliação:
França